AHK-Cu vs Minoxidil
A side-by-side research comparison of AHK-Cu and Minoxidil across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AHK-Cu | Minoxidil |
|---|---|---|
| Full name | AHK-Cu (Alanine-Histidine-Lysine Copper Peptide) | Minoxidil (Rogaine) |
| Category | Hair Growth | Hair Growth |
| Status | Cosmetic research peptide | FDA Approved (OTC) |
| Mechanism | Delivers copper to tissue and signals angiogenesis and growth-factor activity (notably VEGF) around hair follicles, promoting follicle vascularization, prolonging the anagen (growth) phase, and supporting collagen production. | Opens ATP-sensitive potassium channels in vascular smooth muscle and hair follicle cells. Increases blood flow and nutrient delivery to follicles. Prolongs anagen (growth) phase and stimulates VEGF expression for neovascularization around follicles. |
| Molecular weight | ~403 Da (with copper) | 209.25 Da |
| Half-life | Topical (local action) | ~4 hours (systemic); active in follicle for 22h |
| Bioavailability | Topical (serum/solution); local delivery | ~95% oral; topical: local depot effect |
| Typical dose | ~0.5-2 mg/mL topical serum | 5% topical (1mL 2x/day) or 2.5-5 mg oral |
| Frequency | 1-2x daily on scalp | Twice daily (topical) or once daily (oral) |
| Route | Topical | Topical solution/foam or oral tablet |
AHK-Cu reported benefits
- Hair follicle support and growth signaling
- Follicle vascularization (VEGF)
- Prolongs anagen growth phase
- Collagen and skin support
- Antioxidant copper delivery
Minoxidil reported benefits
- Stimulates new hair growth
- Works independently of DHT pathway
- OTC availability
- Effective for both sexes
- Prolongs anagen phase
- Can combine with any other treatment
Related comparisons
Research and educational reference only. Not medical advice.